Silo Pharma Secures European Patent For Novel PTSD Prevention Therapy, Stock Up
Silo Pharma, a developmental-stage biopharmaceutical company, holds an exclusive license from Columbia University for the patent application titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress”. The allowed claims focus on methods to prevent stress-induced fear, depressive-like behavior, and related affective disorders by targeting the serotonin 4 (5-HT4) receptor pathway. Unlike traditional treatments that primarily manage symptoms, this approach aims to build resilience against stress before it manifests.
Eric Weisblum, CEO of Silo Pharma, described the development as a “high-value milestone” that strengthens the company’s intellectual property portfolio and positions its 5-HT4 program as a proactive solution for stress-related conditions. The patent, once finalized, will cover major European markets, with the company also exploring Unitary Patent protection and national validations to maximize reach.
Why It Matters
Stress-related psychiatric disorders, including PTSD, remain a massive and underserved market worldwide. Current therapies often focus on alleviating symptoms after they appear, but Silo’s strategy represents a shift toward prevention. By targeting pathways linked to stress resilience, the company hopes to open new doors in mental health treatment.
Beyond this patent, Silo Pharma is advancing several programs:
-SPC-15: A therapy candidate for PTSD & Stress Disorders/ Mental Health. Licensed from Columbia University, this program is progressing through preclinical development with an IND filing expected in 2026.
-SP-26: Focused on fibromyalgia and chronic pain. Currently in the preclinical stage, with data readouts anticipated in 2026.
-SPC-14: A preclinical program focused on neuroinflammation and cognitive decline, with 2026 data expected.
-SPU-16 Peptide, a neurology program targeting multiple sclerosis, is in optimization and proof-of-concept studies, with preclinical data expected in 2026.
This diversified pipeline underscores Silo’s strategy of combining conventional drug delivery systems with novel approaches, including psychedelic-based therapeutics, to address underserved conditions.
Looking Ahead
With growing global attention on mental health, Silo Pharma’s European patent allowance underscores its ambition to become a leader in CNS therapeutics. The company’s proactive approach to stress prevention could reshape how clinicians and patients think about managing psychiatric disorders in the future.
SILO has traded between $0.22 and $1.19 over the past year. The stock closed Monday’s trading at $0.35, up 2.95%. During the overnight trading, the stock is at $0.59, up 66.84%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Discover more from stock updates now
Subscribe to get the latest posts sent to your email.
